Fig. 1

MPN disease relapse in a JAK2V617F-bearing vascular niche following lethal irradiation and marrow transplantation. A A murine model of MPN disease relapse established by marrow transplantations. B Peripheral blood CD45.1 chimerism following transplantation of wild-type (WT) CD45.1 marrow cells into lethally irradiated Tie2FF1 mice or Tie2-cre control mice (CD45.2) (n  =  8–12 mice in each group). C Tie2FF1 recipients with mixed chimerism developed both neutrophilia and thrombocytosis (n  =  5–8 mice in each group). D Total marrow Lin⁻cKit⁺Sca1⁺CD150⁺CD48⁻ HSCs (n  =  4–9 mice in each group). E Lin⁻cKit⁺Sca1⁺ (LSK) cell proliferation rate in relapse (left) and remission (right) Tie2FF1 recipient mice, measured by in vivo BrdU labeling (left: n  =  6 mice in each group; right: n  =  4 mice in each group). F Cellular apoptosis rate of wild-type and JAK2V617F mutant LSKs in relapse (left) and remission (right) Tie2FF1 recipient mice, measured by activated caspase-3 staining using flow cytometry analysis (left: n  =  4–6 mice in each group; right: n  =  3–5 mice in each group). G Cellular senescence rate of wild-type and JAK2V617F mutant LSKs in relapse (left) and remission (right) Tie2FF1 recipient mice, measured by SA-b-Gal activity using flow cytometry analysis (left: n  =  6 mice in each group; right: n  =  4–5 mice in each group). *P  <  0.05